Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases.

@article{Bagan2005AvascularJO,
  title={Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases.},
  author={J. Bagan and J. Murillo and Y. Jim{\'e}nez and R. Poveda and M. Mili{\'a}n and J. Sanchis and F. Silvestre and C. Scully},
  journal={Journal of oral pathology \& medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology},
  year={2005},
  volume={34 2},
  pages={
          120-3
        }
}
  • J. Bagan, J. Murillo, +5 authors C. Scully
  • Published 2005
  • Medicine
  • Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
BACKGROUND We present a series of 10 patients with osteonecrosis of the jaws (ONJ) that appeared following cancer chemotherapy. MATERIAL AND METHODS Of the 10 cases with ONJ, six had bone metastases from breast cancers and the other four had multiple myeloma. We analysed the location of bone metastases, as well as the characteristics of the ONJ, and the drugs with which they had been treated for their bone metastases. RESULTS Of the 10 patients, all had ONJ in the mandible; 50% also had… Expand
Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients.
TLDR
The case report of an osteonecrosis of the jaw following multi-drug therapy for sarcoidosis adds a further and non-cancerous condition to the newly described entity of bisphosphonate-associated jaw necrosis. Expand
A case of osteonecrosis of the maxilla associated with the use of a bisphosphonate
TLDR
Osteonecrosis of the jaw is being reported more frequently in patients receiving bisphosphonates, and special precautions should be taken in such patients in dental practice. Expand
Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature.
TLDR
The findings in patients and the literature review suggest that the most common clinical presentation of ONJ is pain and exposed bone of the mandible or maxilla and the medical community needs to be aware of the association between bisphosphonate usage and ONJ. Expand
A case of osteonecrosis of the jaw in a breast cancer patient with bone metastases receiving long-term treatment with bisphosphonates
TLDR
Complications and treatment of ONJ in a breast cancer patient with bone metastases who received long-term treatment with BPs are described and medical oncologists need to recognize ONJ as a serious side effect of BP treatment. Expand
Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.
  • A. Badros, D. Weikel, +8 authors T. Meiller
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
ONJ appears to be time-dependent with higher risk after long-term use of bisphosphonates in older MM patients often after dental extractions, and trials addressing the benefits/risks of continuing bisph phosphonate therapy are needed. Expand
Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.
TLDR
It is suggested that both factors may be involved in osteolytic mechanisms and Actinomyces is involved in the chronic, non-healing inflammatory processes as a characteristic feature of both diseases. Expand
Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment.
TLDR
Jaw osteonecrosis appears to be associated with the intra-venous use of bisphosphonates, and dental professionals should be aware of this potentially serious complication in periodontal patients receiving long-term treatment with bisph phosphonates. Expand
Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases.
TLDR
In this series, most patients improved with conservative surgical debridement and Prospective clinical trials would enable clinicians to make accurate judgments about risk, treatment, and outcome for patients with BONJ. Expand
Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
Cases of osteonecrosis of the jaw (ONJ) have been reported with an increasing frequency over the past 5 years. ONJ is most often identified in patients with cancer who are receiving intravenousExpand
Osteonecrosis in the jawbone induced by bisphosphonates – review of literature and case report
TLDR
The high level of suspicion for osteonecrosis in the jaw should be applied in everyone who uses bisphosphonates andAntibiotic therapy seems to be the most effective way to control the necrotic lesions. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 17 REFERENCES
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.
TLDR
In view of the current trend of increasing and widespread use of chronic bisphosphonate therapy, the observation of an associated risk of osteonecrosis of the jaw should alert practitioners to monitor for this previously unrecognized potential complication. Expand
Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients--a report of a thirty year retrospective review.
TLDR
The data suggest that osteoradionecrosis has a multifactorial aetiology and a very close follow-up of tumour patients and a strict prophylactic management are required. Expand
A case of maxillary necrosis.
  • M. Pogrel, Craig Miller
  • Medicine
  • Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • 2003
TLDR
Despite the absence of a definitive diagnosis, in the presence of an increasing region of bone necrosis in the left maxilla, a left inferior hemimaxillectomy was performed to remove all necrotic tissue and to reach healthy bleeding tissue. Expand
Alendronate in the treatment of avascular necrosis of the hip.
TLDR
Early experience with the use of alendronate, a bisphosphonate, in AVN of the hip is reported, which is characterized by persistent, often nagging and disabling pain associated with significant reduction in joint movement and mobility. Expand
Prevention and treatment of the consequences of head and neck radiotherapy.
TLDR
In this review, the various possibilities for prevention and/or treatment of radiation-induced changes in healthy oral tissues and their consequences are discussed. Expand
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
TLDR
BPs have in vivo antiangiogenic properties, which could be of relevance to improve therapy and prevention of bone metastasis, and extend the potential clinical use of BPs to patients with early prostate cancer. Expand
Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid
TLDR
It is shown that zoledronic acid has marked antiangiogenic properties that could augment its efficacy in the treatment of malignant bone disease and extend its potential clinical use to other diseases with an angiogenic component. Expand
Alendronate-related oral mucosa ulcerations.
  • M. Gonzalez-Moles, J. Bagán-sebastián
  • Medicine
  • Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • 2000
TLDR
Two clinical cases of patients who developed extensive palatal ulcers as a result of taking alendronate are presented and possible mechanisms implicated in the production of the ulcers are discussed. Expand
Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats
TLDR
Systemic alendronate treatment prevents resorption of necrotic bone during revascularization and in patients with osteonecrosis, bisphosphonates may therefore prevent collapse of the necrotIC bone. Expand
Severe Oral Ulcerations Induced by Alendronate
TLDR
The case of a 54-year-old man suffering from steroid-induced osteoporosis, who presented with severe oral ulcerations due to sucking alendronate tablets instead of swallowing them, underlies the risk of direct mucosal injury with this drug. Expand
...
1
2
...